Sutro, Celgene collaborate on R&D of antibody drugs

12/19/2012 | Genetic Engineering & Biotechnology News

Sutro Biopharma agreed to design and develop new antibody-drug conjugates and bispecific antibodies against two undisclosed targets for Celgene using its cell-free protein synthesis technology. The deal also covers the production of a proprietary Celgene antibody. In return, Celgene will give Sutro an upfront payment and as much as $500 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT